Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact
Login Book a demo
InnoSIGN logo — Comprehensive Pathway Analysis

InnoSIGN

Comprehensive Pathway Analysis

Founded 2022 The Netherlands The Netherlands 5 employees Series A Total: $8.00M Biotechnology, Life Sciences

General Information

Company Name InnoSIGN
Founded Year 2022
Location The Netherlands The Netherlands
Employees 5
Industries Biotechnology, Life Sciences
Funding Stage Series A
Business Model B2B, SaaS, Platform
Revenue Model Subscription, Licensing, Service Fee
Offices as of Oct 2026
Eindhoven, The Netherlands Mason, United States
Social

BounceWatch is an independent company data service, not affiliated with InnoSIGN. To contact InnoSIGN, visit innosignbio.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does InnoSIGN compare?

A PDF of InnoSIGN and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting InnoSIGN soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About InnoSIGN

InnoSIGN, founded in 2022 and headquartered in The Netherlands, is a dynamic player in the Biotechnology and Life Sciences industries. The company’s tagline, "Comprehensive Pathway Analysis," encapsulates its mission to revolutionize disease understanding.

InnoSIGN’s distinguishing feature is its biology-first approach to comprehending signaling pathways through its proprietary platform. This innovative solution quantifies the activity of over 10 critical disease-driving pathways using structured machine learning algorithms honed over a decade of research at Philips. The company’s platform is designed to provide partners with deeper insights, facilitating accelerated discoveries and innovations.

In March 2022, InnoSIGN secured a substantial $8.00M Series A investment from prominent investors including Casdin Capital, Life Science Angels, Thuja Capital, and BOM - Brabant Regional Development Agency. This financial backing signifies strong investor confidence in InnoSIGN's potential to impact the biotech sector significantly.

Business keywords: biotech, precision medicine, pathway analysis, mRNA profiling, signaling pathways, disease driver events, machine learning in biotech, diagnostics, oncology, molecular diagnostics, drug discovery, genomics, qPCR tests, structured ML algorithms, service testing facility

Services & Products

Comprehensive Disease Analysis
Data Interpretation from Omics
Actionable Insights for Drug Development

Target Customers

Pharmaceutical Companies Biotech Firms Research Institutions Healthcare Professionals

Funding Rounds & Investors (1)

View All
Funding Stage Amount Investors Lead Investors Date
Series A $8.00M 4
Casdin Capital Life Science Angels Thuja Capital
Casdin Capital, Life Science Angels +2
01 Mar 2022

InnoSIGN Alternatives & Competitors

View All Alternatives
InnoSIGN vs
Genomics
Genomics United Kingdom

Transforming health, healthcare and drug discovery and development through the power of genomics

186 employees
Biopharma, Biotechnology
InnoSIGN vs
Celldom, Inc.
Celldom, Inc. United States

Find and study cells that make diseases incurable

Seed
8 employees
Biotechnology, Health Care
InnoSIGN vs
Parallel Bio
Parallel Bio United States

Using the immune system to cure disease.

Series A
27 employees
Biotechnology, Health and Wellness
Also compare with: InnoSIGN vs Ozette Ozette View all alternatives

FAQ About InnoSIGN

Comprehensive Pathway Analysis
InnoSIGN was founded in 2022.
InnoSIGN is headquartered in The Netherlands. As of Oct 2026, it also has offices in Eindhoven, The Netherlands and Mason, United States.
InnoSIGN operates in Biotechnology and Life Sciences. Its work centres on biotech, precision medicine, pathway analysis and mRNA profiling. Its customers include Pharmaceutical Companies, Biotech Firms and Research Institutions.
InnoSIGN has a B2B, SaaS and Platform business model. Its revenue comes from Subscription, Licensing and Service Fee.
InnoSIGN has approximately 5 employees.
InnoSIGN has completed 1 funding round, raising a total of $8.00M. The latest funding stage is Series A.
InnoSIGN offers: Comprehensive Disease Analysis, Data Interpretation from Omics, Actionable Insights for Drug Development.
Top alternatives and competitors to InnoSIGN include Genomics, Celldom, Inc., Parallel Bio, Galatea Bio Inc., Ozette. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
InnoSIGN and Genomics are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for InnoSIGN, https://bouncewatch.com/company/innosign, updated 22 August 2026. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes